TokenPost·
BeOne Reports 36% Response Rate for Liver Cancer Drug in Phase 1
36%
drug response rate
The result came from 25 evaluable patients given 450 milligrams every three weeks; BeOne plans larger trials by the end of 2026.
More news
- TokenPostMicrosoft and Alphabet Set Oct. 28 Earnings; Amazon Follows Oct. 29
- TokenPostBackpack CEO Armani Ferrante Amplifies Post About Tokenomics Plan
- TokenPostSEC Extends Deadline for TerraUSD Fund Distribution Plan to 2027
- CoinGapeWhat’s Next for SpaceX Stock Price as $40B Debt Deal Faces Headwinds After Global AI Rout
- TokenPostElectrum Releases Version 4.8.3 to Fix Serious Security Issue
- TokenPostERC-8004 Draft Proposes Registries for AI Agent Identity and Reputation